Magnetic Resonance Imaging In Acute ST-Elevation Myocardial Infarction
- Conditions
- Acute ST-Elevation Myocardial Infarction
- Interventions
- Diagnostic Test: Cardiovascular Magnetic Resonance Imaging
- Registration Number
- NCT04113356
- Lead Sponsor
- Medical University Innsbruck
- Brief Summary
Cardiovascular magnetic resonance imaging enables comprehensive assessment of cardiovascular function, morphology and pathology. The investigators aim to evaluate the nature and clinical significance of magnetic resonance imaging parameters in patients presenting with first acute ST-elevation myocardial infarction.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1500
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description ST-Elevation Myocardial Infarction Cardiovascular Magnetic Resonance Imaging Patients with acute ST-elevation myocardial infarction treated with primary percutaneous coronary intervention
- Primary Outcome Measures
Name Time Method Occurence of major adverse cardiovascular events 1 - 5 years
- Secondary Outcome Measures
Name Time Method Aortic pulse wave velocity and distensibility by phase contrast imaging baseline, 4 months and 12 months Cardiac function by cine imaging baseline, 4 months and 12 months Parameters of cardiac function by transthoracic echocardiography baseline, 4 months and 12 months Cardiac autonomic function baseline, 4 months and 12 months Skin sympathetic nerve activity
Plaque volume by 3D ultrasound baseline, 12 months Infarct size assessment (% of left ventricular myocardial mass) baseline, 4 months and 12 months Assessment of infarct transmurality grade (%) with late gadolinium enhancement imaging baseline, 4 months and 12 months Occurence and area of microvascular obstruction baseline Intramyocardial haemorrhage assessed by T2* imaging baseline, 4 months and 12 months Tissue characterisation by T1, T2 and T2* Mapping baseline, 4 months and 12 months Myocardial deformation by strain analysis baseline, 4 months and 12 months Aortic pulse wave distensibility by phase contrast imaging baseline, 4 months and 12 months Quality of life and invalidity assessment (Global Physical Activity Questionnaire) 1 - 5 years Biomarker release during the acute and subacute phase baseline, 4 months and 12 months biomarker concentrations of hemodynamic stress (n-terminal pro-B-type natriuretic peptide), neurohumoral markers (i.e. neprilysin ng/ml), inflammatory markers (i.e. procalcitonin µg/l) and markers of myocardial injury (i.e. high sensitivity cardiac troponin T ng/l)
Chamber volumes by cine imaging baseline, 4 months and 12 months Stroke volumes by phase contrast imaging baseline, 4 months and 12 months
Trial Locations
- Locations (2)
University Hospital for Radiology
🇦🇹Innsbruck, Austria
University Hospital for Internal Medicine III (Cardiology and Angiology)
🇦🇹Innsbruck, Austria